Dohi T, Nishikawa A, Ishizuka I, Totani M, Yamaguchi K, Nakagawa K, Saitoh O, Ohshiba S, Oshima M
Division of Clinical Biochemistry, National Medical Center, Tokyo, Japan.
Biochem J. 1992 Nov 15;288 ( Pt 1)(Pt 1):161-5. doi: 10.1042/bj2880161.
The detailed substrate specificity of the UDP-GalNAc:sialylparagloboside N-acetylgalactosaminyltransferase to form the Sd(a+) blood group active carbohydrate determinant GalNAc beta 1-4(NeuAc alpha 2-3)Gal was studied using a membrane fraction prepared from human gastric fundic mucosa. Various sialosylated oligosaccharides and gangliosides were examined as acceptor substrates. Oligosaccharide substrates were fluorescence-labelled with 2-aminopyridine, and the transferase activity was quantified by h.p.l.c. using a reversed-phase column. The structures of the products were determined by glycosidase degradation and proton n.m.r. 3'-Sialyl-lactose (II3NeuAcLac), 3'-sialyl-lactotetraose (IV3NeuAcLc4), and 3'-sialyl-lactoneotetraose (IV3NeuAcnLc4) were good substrates for the beta 1-4GalNAc transferase in gastric fundic mucosa, but 6'-sialyl-lactoneotetraose (IV6NeuAcnLc4) or 6'-sialyl-lactose (II6NeuAcLac) were not. Gangliosides with a terminal NeuAc alpha 2-3Gal residue such as GM3, sialylparagloboside, GM1b and GD1a were also studied. The activity of beta 1-4GalNAc transfer to sialylparagloboside was much higher than that to GM2, GM1b or GD1a in spite of them having the same terminal residue. Measurement of the activity of the beta 1-4GalNAc transferase in biopsy specimens demonstrated that the activity was localized in gastric fundic mucosa and was absent in pyloric mucosa, intestinal metaplasia and gastric cancer tissue. Thus the beta 1-4GalNAc transferase present specifically in fundic mucosa required a NeuAc alpha 2-3Gal residue connected to either type-1-chain or type-2-chain oligosaccharides. In glycolipids, the acceptor specificity was restricted to NeuAc alpha 2-3Gal beta 1-4GlcNAc because the NeuAc alpha 2-3Gal beta 1-3GalNAc structure in ganglio-series glycolipids was not a good acceptor substrate.
使用从人胃底粘膜制备的膜部分,研究了UDP-N-乙酰半乳糖胺:唾液酸副球蛋白N-乙酰半乳糖胺基转移酶形成Sd(a+)血型活性碳水化合物决定簇GalNAcβ1-4(NeuAcα2-3)Gal的详细底物特异性。研究了各种唾液酸化寡糖和神经节苷脂作为受体底物。寡糖底物用2-氨基吡啶进行荧光标记,并使用反相柱通过高效液相色谱法定量转移酶活性。通过糖苷酶降解和质子核磁共振确定产物的结构。3'-唾液酸乳糖(II3NeuAcLac)、3'-唾液酸乳糖四糖(IV3NeuAcLc4)和3'-唾液酸新乳糖四糖(IV3NeuAcnLc4)是胃底粘膜中β1-4GalNAc转移酶的良好底物,但6'-唾液酸新乳糖四糖(IV6NeuAcnLc4)或6'-唾液酸乳糖(II6NeuAcLac)不是。还研究了具有末端NeuAcα2-3Gal残基的神经节苷脂,如GM3、唾液酸副球蛋白、GM1b和GD1a。尽管它们具有相同的末端残基,但β1-4GalNAc转移至唾液酸副球蛋白的活性远高于转移至GM2、GM1b或GD1a的活性。活检标本中β1-4GalNAc转移酶活性的测定表明,该活性定位于胃底粘膜,而在幽门粘膜、肠化生和胃癌组织中不存在。因此,胃底粘膜中特异性存在的β1-4GalNAc转移酶需要与1型链或2型链寡糖连接的NeuAcα2-3Gal残基。在糖脂中,受体特异性仅限于NeuAcα2-3Galβ1-4GlcNAc,因为神经节系列糖脂中的NeuAcα2-3Galβ1-3GalNAc结构不是良好的受体底物。